School of Animal and Veterinary Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
Clinical Governance Unit, Murrumbidgee Local Health District, Wagga Wagga, New South Wales, Australia.
Equine Vet J. 2022 Sep;54(5):895-904. doi: 10.1111/evj.13519. Epub 2021 Nov 8.
Marked increases in serum muscle enzyme activity can occur in endurance horses but the diagnostic certainty in predicting cases of myopathy is unclear. Improved understanding of horse management effects on serum muscle enzyme activity as markers of muscle health would assist interpretation of serum muscle enzyme activity and guide management to reduce myopathy risk.
To investigate associations between serum muscle enzyme activity and management factors in endurance horses.
Cross-sectional study.
One hundred endurance horses competing in four endurance events (offering distances of 20-120 km) in south-eastern Australia were observed. Data were collected from official horse logbooks, pre-and post-race serum samples, an owner questionnaire of pre-race and race management of horses and the Australian Endurance Riders Association results database. Multivariable linear regression modelling tested associations between management factors and serum muscle enzyme activity.
First leg speed, distance raced, number of rest days pre-race, and pre-race activity of aspartate aminotransferase (AST) and creatine kinase (CK) explained 47.3% of the variance in post-race CK. As first leg speed increased by 1 km/h, CK activity increased by 25.8% (95% CI 11%-35%). Race distances >80 km increased post-race CK activity by 124% (95% CI 116%-145%). Each additional pre-race rest day increased post-race CK activity by 30.5% (95% CI 11%-42%). Modelling a 10% increase in pre-race CK and pre-race AST activity was associated with post-race CK activity increasing by 7.3% (95% CI 3%-14.4%) and 8.5% (95% CI 0.3%-14.2%) respectively. Horses experiencing training distances >40 km and a greater number of rest days prior to race day developed increased pre-race AST and CK activity respectively.
Owner questionnaires may be subject to bias. Limited data were available to model ride terrain, horse fitness, ration detail and myopathy. Muscle biopsies were not used to confirm myopathy.
Nearly half of the variation in post-race CK activity observed can be attributed to management factors unrelated to myopathy, suggesting increased CK activity may not be pathognomonic for myopathy. We advise caution in relying solely on serum muscle enzyme activity for diagnosis of myopathy until the strength of association between CK and myopathy is further ascertained in future studies.
耐力马的血清肌肉酶活性会显著增加,但预测肌病的诊断确定性尚不清楚。更好地了解马匹管理对血清肌肉酶活性作为肌肉健康标志物的影响,将有助于解释血清肌肉酶活性,并指导管理以降低肌病风险。
研究耐力马的血清肌肉酶活性与管理因素之间的关系。
横断面研究。
对澳大利亚东南部四个耐力赛事(提供 20-120 公里距离)中的 100 匹耐力马进行观察。数据来自官方马匹日志、比赛前后的血清样本、马主对比赛前和比赛期间马匹管理的调查问卷以及澳大利亚耐力骑手协会的比赛结果数据库。多变量线性回归模型测试了管理因素与血清肌肉酶活性之间的关系。
第一阶段速度、比赛距离、赛前休息天数、天冬氨酸氨基转移酶(AST)和肌酸激酶(CK)的赛前活性解释了赛后 CK 变化的 47.3%。第一阶段速度每增加 1 公里/小时,CK 活性增加 25.8%(95%置信区间 11%-35%)。距离超过 80 公里的比赛会使赛后 CK 活性增加 124%(95%置信区间 116%-145%)。每增加一个赛前休息日,赛后 CK 活性增加 30.5%(95%置信区间 11%-42%)。模拟赛前 CK 和 AST 活性增加 10%,与赛后 CK 活性分别增加 7.3%(95%置信区间 3%-14.4%)和 8.5%(95%置信区间 0.3%-14.2%)相关。经历训练距离超过 40 公里和更多赛前休息天数的马,其赛前 AST 和 CK 活性分别增加。
马主调查问卷可能存在偏差。用于建模骑行地形、马匹健康状况、饲料详情和肌病的数据有限。未使用肌肉活检来确认肌病。
观察到的赛后 CK 活性变化的近一半可以归因于与肌病无关的管理因素,这表明 CK 活性增加可能不是肌病的特征性表现。我们建议在进一步确定 CK 与肌病之间的关联强度之前,在诊断肌病时谨慎仅依赖血清肌肉酶活性。